A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

NCT00000712 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

400

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Zidovudine
DRUG: Acyclovir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)